

For Immediate Release

**Alembic Pharmaceuticals Ltd.
Consolidated Results for quarter ended 30.06.2012**

**Revenues up 7 % at Rs 368 crores against Rs. 345 crores in PY
PBT up 7 % at Rs 38.09 crores against Rs. 35.47 crores in PY**

Editors Synopsis

Quarter ended 30th June, 2012

- **Net sales up 7 % at Rs 368 crores for the quarter against Rs. 345 crores in corresponding quarter last year**
- **Domestic formulations sales up 14 % for the quarter at Rs. 197 crores against Rs. 172 crores in corresponding quarter last year**
- **Export sales at Rs. 139 crores against Rs. 137 crores for the corresponding quarter last year**
- **EBITDA at 14.3 % at Rs. 52.27 crores**
- **Net profit after tax for the quarter at Rs. 30.83 crores vis-à-vis Rs. 27.56 crores in P.Y.**

Vadodara, 9th Aug, 2012

Alembic Pharmaceuticals Limited reported a 7% increase in revenues to Rs 368.06 crores for the quarter ended 30th June 2012, compared to Rs 344.72 crores in the corresponding quarter last year.

The Company posted 7% growth in profit before tax at Rs. 38.09 crores for the quarter ended 30th June 2012 against Rs 35.47 crores posted in corresponding quarter last fiscal.

The net profit grew by 12% at Rs. 30.83 crores for the quarter ended 30th June 2012 against Rs. 27.56 crores in corresponding quarter last fiscal.

Domestic Formulations Business

The Domestic formulations business posted sales of Rs. 197.24 crores against Rs. 172.44 crores with a 14% growth over the corresponding quarter of the previous year.

Alembic maintained market share of 1.62%

Alembic has four brands in the list of top 300 brands of industry i.e. 'Azithral', 'Roxid', 'Althrocine' and 'Wikoryl'.

Some of the specialty segments which the company entered recently are showing good progress.

The company launched a dermatology division during the quarter with a field force of 100 people. This will further add to the basket of specialty products and growth in the future.

API

For the quarter, Export API recorded sales of Rs. 83.48 crores against Rs. 60.73 crores registering growth of 37% while domestic API recorded sales of Rs. 30.47 crores against Rs. 34.75 crores in corresponding quarter last year.

International Generics

International Generic Formulation sales is Rs. 46.05 crores against Rs. 61.15 crores over the corresponding quarter last year. De-growth was in line with our expectations due to price erosion, product mix and capacity constraint.

Cumulative ANDA filings of the Company stand at 49. Cumulative ANDA approvals now stands at 20 (including two tentative approvals).

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in Lacs)

Particulars			
	Q1 FY13	Q1 FY12	% Change
Formulation			
Domestic	19724	17244	14%
International Branded	755	1132	(-)33%
International Generics	4605	6115	(-)25%
API			
Domestic	3047	3475	(-)12%
International	8348	6073	37%
Export incentives	327	433	(-)24%
Total	36806	34472	7%

The Profit break-up for the quarter is as under:

(Rs. in Lacs)

Particulars	Q1 FY13	Q1 FY12	% change
Operating Income	5227	5035	4%
Profit Before Tax	3809	3547	7%
Net Profit after Tax	3083	2756	12%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information:

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in

Alembic Pharmaceuticals Limited